Literature DB >> 28681122

Lewis x Antigen is Associated to Head and Neck Squamous Cell Carcinoma Survival.

Martín E Rabassa1, Adrian Pereyra1, Liliana Pereyra1, Amada Segal-Eiras1, Martín C Abba1, Maria V Croce2.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is an aggressive disease with poor prognosis without appropriate prognostic markers. Previous research shows that Lewis antigens have been involved in carcinoma dissemination and patients´ survival. Fucosyl and sialyltransferases are the enzymes implicated in the Lewis antigens synthesis. The purpose of this study was to evaluate the prognostic utility of Lewis antigens in HNSCC. We conducted a prospective research including histological samples from 79 patients with primary HNSCC. Lewis x and sialyl Lewis x expression were detected by immunohistochemistry; patient's data, progression free, and overall survival were documented. A statistical correlation study of antigenic expression and patients´ histopathological variables was performed. Cox regression models with internal validation procedures were employed to analyze survival data. By immunohistochemistry, Lewis x was detected in 34/79 (43%) tumor samples, while sialyl Lewis x only in 11/79 (14%). Lewis x expression showed a positive correlation with tumor differentiation and a better overall survival for Lewis x + patients was detected. Moreover, multivariate Cox's regression analysis showed that Lewis x is an independent predictor of better overall survival. The in silico analysis supported the presence of deregulated fucosyl (FUT4) and sialyltransferase (ST3GAL4) in the Lewis synthetic pathway related to patient survival. These results suggest that Lewis x expression is associated with a better outcome in patients with HNSCC.

Entities:  

Keywords:  Antigenic expression; Head and neck squamous cell carcinoma; Risk and prognostic factors; Survival

Mesh:

Substances:

Year:  2017        PMID: 28681122     DOI: 10.1007/s12253-017-0269-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  40 in total

Review 1.  Reflections on glycobiology.

Authors:  S Roseman
Journal:  J Biol Chem       Date:  2001-09-11       Impact factor: 5.157

2.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

Review 3.  Fucosylation in prokaryotes and eukaryotes.

Authors:  Bing Ma; Joanne L Simala-Grant; Diane E Taylor
Journal:  Glycobiology       Date:  2006-09-14       Impact factor: 4.313

4.  Relevance of βGal-βGalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients.

Authors:  Karin Milde-Langosch; Dina Schütze; Leticia Oliveira-Ferrer; Harriet Wikman; Volkmar Müller; Patrick Lebok; Klaus Pantel; Christine Schröder; Isabell Witzel; Udo Schumacher
Journal:  Breast Cancer Res Treat       Date:  2015-05-15       Impact factor: 4.872

5.  Lewis X oligosaccharides-heparanase complex targeting to DCs enhance antitumor response in mice.

Authors:  Hongjie Chen; Bangqing Yuan; Zhaocong Zheng; Zheng Liu; Shousen Wang
Journal:  Cell Immunol       Date:  2011-03-24       Impact factor: 4.868

6.  Identification of sialyl Lewis-x in squamous cell carcinoma of the head and neck.

Authors:  R W Farmer; W J Richtsmeier; R L Scher
Journal:  Head Neck       Date:  1998-12       Impact factor: 3.147

7.  Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer.

Authors:  María V Croce; Marina T Isla-Larrain; Carina E Rua; Martín E Rabassa; Sandra J Gendler; Amada Segal-Eiras
Journal:  J Histochem Cytochem       Date:  2003-06       Impact factor: 2.479

8.  Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia.

Authors:  Asa Rangert Derolf; Elisabet Björklund; Joanna Mazur; Magnus Björkholm; Anna Porwit
Journal:  Leuk Lymphoma       Date:  2008-07

9.  Differential expression of MUC1 and carbohydrate antigens in primary and secondary head and neck squamous cell carcinoma.

Authors:  María V Croce; Martín E Rabassa; Adrián Pereyra; Amada Segal-Eiras
Journal:  Head Neck       Date:  2008-05       Impact factor: 3.147

10.  MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis.

Authors:  Martín E Rabassa; María V Croce; Adrián Pereyra; Amada Segal-Eiras
Journal:  BMC Cancer       Date:  2006-10-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.